10-Q: Greater Cannabis Faces Financial Headwinds, CEO Gains Control

The Greater Cannabis Company reported a significant increase in net loss for the nine months ended September 30, 2025, alongside a reverse stock split and a new preferred stock issuance granting its CEO voting control.

Summary

• Reported a net loss of $669,369 for the nine months ended September 30, 2025, a substantial increase from $135,693 in the same period of 2024.
• Cash balance decreased to $21,355 as of September 30, 2025, from $57,368 at December 31, 2024.
• Total current liabilities rose to $1,129,697 at September 30, 2025, from $898,058 at December 31, 2024, resulting in negative working capital of $1,108,342.
• Operating expenses increased to $129,199 for the nine months ended September 30, 2025, compared to $118,651 for the prior year.
• Other expenses were significantly impacted by a $232,220 loss on conversion of notes payable and $306,323 in note default penalties and interest.
• The company executed a 1-for-1,500 reverse stock split effective October 16, 2025, reducing outstanding common shares from approximately 1.35 billion to 900,256.
• A new class of Series B Convertible Preferred Stock was created and issued to CEO Aitan Zacharin, granting him 51.0% voting control in exchange for waiving $20,000 in accrued compensation.
• The company is awaiting the sourcing of specialized active pharmaceutical ingredients (API) to proceed with a Phase 2 Clinical Trial for its novel cannabinoid therapeutic.
• Financial statements for the three months ended March 31, 2025, were restated to correct terms of a note agreement, adding $138,906 in default penalties and interest.

Sentiment

Score: 2

Explanation: The company faces severe financial distress with increasing losses, declining cash, and a 'going concern' warning. While there's progress in clinical trial approvals, the indefinite delay due to API sourcing and the explicit need for significant capital raise without clear funding sources are major concerns. The reverse stock split and CEO gaining voting control are often signs of a company in a challenging position.

Positives

• Net cash used in operating activities improved to $(36,013) for the nine months ended September 30, 2025, from $(104,577) in the prior year.
• Received approval from the Israel Ministry of Health to proceed with a Phase II Clinical Trial for its cannabinoid therapeutic.
• Preclinical studies for the cannabinoid therapeutic have been concluded.

Negatives

• Significant increase in net loss to $669,369 for the nine months ended September 30, 2025, compared to $135,693 in the prior year.
• Cash balance declined by over 60% from $57,368 at December 31, 2024, to $21,355 at September 30, 2025.
• Total current liabilities increased to $1,129,697, leading to a substantial negative working capital of $1,108,342.
• Incurred $232,220 in loss on conversion of notes payable and $306,323 in note default penalties and interest for the nine months ended September 30, 2025.
• The company has no revenue for the periods presented.
• Substantial doubt exists about the company's ability to continue as a going concern through September 2026.

Risks

• Inability to remediate identified material weaknesses in internal control over financial reporting and disclosure controls and procedures.
• Failure to meet requirements of agreements under which business interests were acquired, potentially leading to loss of operating rights.
• Inability to secure additional financing in the near future to commence and sustain planned development and growth.
• Difficulty attracting, retaining, and motivating qualified personnel (employees, consultants, contractors).
• Risks and uncertainties related to the various industries and operations the company is engaged in.
• Uncertainty that future growth, development, or expansion will be consistent with expectations based on feasibility studies.
• Inherent uncertainty of business operations, including profit, cost of goods, production costs, and potential for unexpected costs and expenses.
• Risks related to commodity price fluctuations.
• Uncertainty of profitability due to a history of losses.
• Risks related to failure to obtain adequate financing on a timely basis and on acceptable terms for planned development projects.
• Risks related to environmental regulation and liability.
• Risks related to tax assessments.
• Other risks and uncertainties related to prospects, properties, and business strategy.

Future Outlook

The company plans to further develop its novel cannabinoid therapeutic and conduct clinical studies, which are expected to require an investment of up to $1,000,000 and up to two years to finalize from the start date. It also intends to concentrate on cannabis-related investment and development opportunities through direct equity investments, joint ventures, licensing agreements, or acquisitions. The company needs to raise additional funds to finance the cost of the Phase II Clinical Trial and expects to continue incurring negative cash flows until its business generates sufficient cash inflows.

Management Comments

• "Our future plans include securing additional funding sources."
• "We expect to continue to incur negative cash flows until such time as our business generates sufficient cash inflows to finance our operations and debt service requirements."
• "We have therefore concluded there is substantial doubt about our ability to continue as a going concern through September 2026."
• "The Company plans to further develop this therapeutic and conduct clinical studies to further substantiate its safety and efficacy beginning in neuropsychiatric disorders."

Industry Context

The company operates in the highly speculative and capital-intensive cannabinoid therapeutics and medical cannabis industry. Its focus on neuropsychiatric disorders positions it in a niche with high unmet medical needs but also significant regulatory hurdles and long development timelines. The reliance on external funding for clinical trials is typical for early-stage biotech companies, but the "going concern" warning and lack of revenue highlight the significant challenges in this competitive and evolving sector. The reverse stock split and CEO gaining voting control are often seen in micro-cap companies struggling to maintain listing requirements or attract investment, potentially signaling a restructuring effort in a difficult market.

Comparison to Industry Standards

• The company's lack of revenue and significant net losses are common for early-stage pharmaceutical development companies, especially those in clinical trials. However, the magnitude of the accumulated deficit and negative working capital, coupled with the "going concern" warning, indicates a more precarious financial position than many peers who might have more robust funding or earlier-stage revenue streams.
• The need for up to $1,000,000 for clinical studies over two years is a relatively modest budget for Phase II trials in the pharmaceutical industry, suggesting either a very focused trial or a highly capital-constrained approach compared to larger biotech firms.
• The reverse stock split is a common tactic for companies to increase their share price to meet exchange listing requirements or improve market perception, but it does not fundamentally change the company's valuation or operational health. Many small-cap cannabis companies have resorted to similar actions amidst market downturns.
• The CEO gaining 51% voting control through preferred stock conversion is a significant corporate governance event, potentially consolidating power in a way that is not always seen in more mature or well-funded industry players, where broader shareholder influence is often maintained.

Management Changes

Corporate Governance

Related Party Transactions

• Loans payable to Elisha Kalfa and Yonah Kalfa (holders of Series A Convertible Preferred stock) totaling $180,000.
• Loan from Fernando Bisker and Sigalush, LLC (holders of Series A Convertible Preferred stock) totaling $80,000.
• These related party loans are non-interest bearing and are to be repaid after the company raises $1,500,000 or generates sufficient revenue, with an option for conversion into common stock if capital is insufficient.
• Issuance of Series B Convertible Preferred Stock to Aitan Zacharin (CEO and sole director) in consideration of his waiving $20,000 in accrued but unpaid compensation.

Stakeholder Impact

• Shareholders: Significant dilution from past conversions of notes payable, further dilution potential from future capital raises, and a 1-for-1,500 reverse stock split. The creation of Series B Preferred Stock gives the CEO 51% voting control, potentially reducing influence of common shareholders. The "going concern" warning poses a significant risk to investment value.
• Employees/Consultants: Accrued officers compensation of $460,350 indicates potential payment delays or reliance on equity for compensation.
• Creditors: The company has significant current liabilities, including accrued interest and note default penalties, and a "going concern" warning, indicating high risk for creditors.
• Customers: No current product sales, so direct customer impact is minimal, but future product availability depends on successful clinical trials and funding.

Next Steps

• Source specialized active pharmaceutical ingredients (API) for the Phase 2 Clinical Trial.
• Raise additional funds to finance the cost of the Phase 2 Clinical Trial.
• Conduct the Phase 2 Clinical Trial, expected to take 18 to 24 months from the start date.
• Submit an application to the FDA for regulatory process after obtaining clinical data from Phase 2.
• Remediate identified material weaknesses in internal control over financial reporting and disclosure controls and procedures, as capital resources permit.
• Continue to pursue cannabis-related investment and development opportunities.

Key Dates

Recommendation

The company exhibits severe financial distress with a substantial increase in net loss, critically low cash reserves, and a significant negative working capital position. The explicit "going concern" warning indicates a high probability of future financial instability or failure. While clinical trial progress is noted, the indefinite delay in sourcing API and the urgent need for capital without clear funding sources present major operational and financial hurdles. The reverse stock split and the CEO consolidating voting control, while potentially aimed at stability, do not address the fundamental financial weaknesses and may signal further challenges for common shareholders. The accumulation of note default penalties further underscores poor financial management.

Keywords

Cannabinoid therapeutics, Autism treatment, Schizophrenia treatment, Parkinson's disease, Alzheimer's disease, Neuropsychiatric disorders, Clinical trials, Phase 2 clinical trial, SEC filing, 10-Q, Reverse stock split, Preferred stock, Voting control, Going concern, Biotechnology, Pharmaceutical development, Medical cannabis, Drug delivery, API sourcing, Financial distress